| Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908) |
|---|
| 08/08/2001 | CN1307588A Compounds with growth hormone releasing properties |
| 08/08/2001 | CN1307584A Macrolide LHRH antagonists |
| 08/08/2001 | CN1307481A Methods for treating hot flashes and gynaecomastia |
| 08/08/2001 | CN1069317C Novel indane-2-mercaptoacetamide disulfide derivs, useful as inhibitors of enkephaliinase |
| 08/07/2001 | US6271243 Pharmaceutical composition |
| 08/07/2001 | US6271200 Proteinic drug delivery system using aerosolized membrane-mimetic amphiphiles |
| 08/02/2001 | WO2001055392A2 Nuclear hormone receptors |
| 08/02/2001 | WO2001055336A2 Methods and materials relating to cd84-like polypeptides and polynucleotides |
| 08/02/2001 | WO2001055134A2 Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vassopressin receptors |
| 08/02/2001 | WO2001055130A2 Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vasopressin receptors |
| 08/02/2001 | WO2001055122A1 Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses |
| 08/02/2001 | WO2001055119A2 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| 08/02/2001 | WO2001055114A1 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors |
| 08/02/2001 | WO2001055106A2 Novel melanocortin receptor agonists and antagonists |
| 08/02/2001 | WO2001055105A1 N-substituted 2-cyanopyroles and -pyrrolines which are inhibitors of the enzyme dpp-iv |
| 08/02/2001 | WO2001054741A1 A medicinal aerosol formulation |
| 08/02/2001 | WO2001054715A1 Use of fsh for treating infertility |
| 08/02/2001 | WO2001054711A2 Use of neurotoxins for treating diabetes |
| 08/02/2001 | WO2001054699A1 Selective estrogen receptor modulators in combination with estrogens |
| 08/02/2001 | WO2001054694A1 Tetrahydropyrimidone inhibitors of fatty acid binding protein and method |
| 08/02/2001 | WO2001054667A1 Electrospun pharmaceutical compositions |
| 08/02/2001 | WO2001004305A3 Human proteins involved in detoxification |
| 08/02/2001 | WO2000066564A8 Benzimidazolones and analogues and their use as progesterone receptor ligands |
| 08/02/2001 | WO2000047603A3 16-hydroxyestratrienes as selective estrogens |
| 08/02/2001 | US20010010913 Isolated polypeptide |
| 08/02/2001 | EP1144431A3 16-hydroxyestratrienes as selective estrogens |
| 08/02/2001 | CA2398728A1 Novel melanocortin receptor agonists and antagonists |
| 08/02/2001 | CA2398564A1 Nuclear hormone receptors |
| 08/02/2001 | CA2398546A1 Methods and materials relating to cd84-like polypeptides and polynucleotides |
| 08/02/2001 | CA2397680A1 Use of fsh for treating infertility |
| 08/02/2001 | CA2396640A1 Electrospun pharmaceutical compositions |
| 08/02/2001 | CA2396596A1 Tetrahydropyrimidone inhibitors of fatty acid binding protein and method |
| 08/02/2001 | CA2395730A1 Selective estrogen receptor modulators in combination with estrogens |
| 08/01/2001 | EP1120113A2 Use of selective ligands for treatment of disease states responsive to steroid or steroid-like hormone |
| 08/01/2001 | EP1119629A2 Oxidoreductase molecules |
| 08/01/2001 | EP1119361A2 Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities |
| 08/01/2001 | EP1119334A1 Two chamber cartridge for atomizers |
| 08/01/2001 | CN1306512A Heterocyclic inhibitors of P38 |
| 08/01/2001 | CN1306511A Novel heterocyclic compounds |
| 07/31/2001 | US6268361 Estrogen dependent disorders including cancer, enodmetriosis, etc |
| 07/31/2001 | US6268151 Antisense modulation of macrophage migration inhibitory factor expression |
| 07/31/2001 | US6267994 Use of extract of cimicifuga racemosa |
| 07/31/2001 | US6267982 Estradiol dissolved in (meth)acrylate copolymer by drying and present in at least three times saturation solubility concentration measured at 95% relative air humidity, enclosed in moisture-tight package with low humidity air |
| 07/26/2001 | WO2001053346A1 Human cystine knot polypeptide |
| 07/26/2001 | WO2001053321A2 Use of trilostane and its derivatives, optionally in combination with tamoxifen or raloxifene in the treatment of estrogen-dependent cancers e.g. breast, prostate and uterus cancers |
| 07/26/2001 | WO2001053317A1 Antisense modulation of macrophage migration inhibitory factor expression |
| 07/26/2001 | WO2001053285A1 Food product and process |
| 07/26/2001 | WO2001053263A1 Corticotropin releasing factor antagonists |
| 07/26/2001 | WO2001053254A1 Calcilytic compounds |
| 07/26/2001 | WO2001052903A1 Method for nucleic acid transfection of cells |
| 07/26/2001 | WO2001052862A1 Antisense modulation of glycogen synthase kinase 3 beta expression |
| 07/26/2001 | WO2001052857A1 Drospirenone for hormone replacement therapy |
| 07/26/2001 | WO2001052829A2 Statin-type bone growth stimulators |
| 07/26/2001 | WO2001001748A3 Peptide compounds that bind her2 |
| 07/26/2001 | DE10100779A1 Formulierung Formulation |
| 07/26/2001 | DE10001172A1 Templatieren von Feststoffpartikeln mit Polymermultischichten Templating of solid particles with polymer multilayers |
| 07/26/2001 | CA2397802A1 Calcilytic compounds |
| 07/26/2001 | CA2397659A1 Statin-type bone growth stimulators |
| 07/26/2001 | CA2397633A1 Corticotropin releasing factor antagonists |
| 07/26/2001 | CA2397565A1 Food product and process |
| 07/26/2001 | CA2397492A1 Method for nucleic acid transfection of cells |
| 07/26/2001 | CA2397205A1 Antisense modulation of macrophage migration inhibitory factor expression |
| 07/26/2001 | CA2396697A1 Antisense modulation of glycogen synthase kinase 3 beta expression |
| 07/26/2001 | CA2396283A1 Human cystine knot polypeptide |
| 07/26/2001 | CA2332214A1 Compositions and methods for treating osteoporosis and lowering cholesterol |
| 07/25/2001 | EP1118323A2 Method of reducing morbidity and the risk of mortality |
| 07/25/2001 | EP1117785A1 Human kinesin-like motor protein |
| 07/25/2001 | EP1117648A1 Tetrahydroquinoline derivatives having selective activity for retinoid x receptors |
| 07/25/2001 | EP1117628A1 2, 4-pentadienoic acid derivatives having selective activity for retinoid x (rxr) receptors |
| 07/25/2001 | EP1117444A2 Hydrogels and water soluble polymeric carriers for drug delivery |
| 07/25/2001 | EP1117425A2 Methods for the treatment of non-thyroid disorders |
| 07/25/2001 | EP1117420A1 Pharmaceutical compositions based on alpha-cyclodextrin for the oral administration of lh-rh analogues |
| 07/25/2001 | EP1117402A2 Antibiotic compositions for treatment of the eye, ear and nose |
| 07/25/2001 | EP1117395A1 Compounds for the treatment of estrogen-dependent illnesses and methods for making and using the same |
| 07/25/2001 | EP1117390A1 Mucosal originated drug delivery systems and animal applications |
| 07/25/2001 | CN1305490A Improved processing for preparing schift base adducts of amines with i(o)-hydroxy aldehydes and compositions of matter based thereon |
| 07/25/2001 | CN1305480A Pyrolo [2,3-d] pyrimidine compounds |
| 07/25/2001 | CN1305479A Pyrrolo [2,3-d] pyrmidine compounds |
| 07/25/2001 | CN1305477A Azablicyclic 5-HT, receptor ligands |
| 07/25/2001 | CN1305457A Novel antiestrogens, method for production thereof and their pharmaceutical application |
| 07/25/2001 | CN1305377A Methods for increasing levels of acetylcholine |
| 07/25/2001 | CN1305373A Therapeutic combinations comprising selective estrofen receptor modulator and parathyroid hormone |
| 07/24/2001 | US6265562 Nucleotide sequences coding transcription factor; for the treatment and prevention of infection, tumors, leukemias, autoimmune disease, allergies, arthritis, inflammation, organ rejection, graft versus host disease and coagulation defects |
| 07/24/2001 | US6265547 Polypeptide for use in diagnosis, treatment, and prevention of cancer, nervous system disorders |
| 07/24/2001 | CA2331847A1 Methods of treating diabetic cardiomyopathy using glycogen phosphorylase inhibitors |
| 07/19/2001 | WO2001051638A2 Drug metabolizing enzymes |
| 07/19/2001 | WO2001051493A1 Benzosulfones with calcium antagonist activity |
| 07/19/2001 | WO2001051454A1 Compounds and compositions for delivering active agents |
| 07/19/2001 | WO2001051196A1 Templating of solid particles by polymer multilayers |
| 07/19/2001 | WO2001051074A1 Methods for treating pancreatic disorders |
| 07/19/2001 | WO2001051058A1 Use of a cyclic ether for the preparation of medicaments affecting glucose tolerance |
| 07/19/2001 | WO2001051055A2 Pharmaceutical compositions containing steroidal structures and uses thereof |
| 07/19/2001 | WO2001050848A2 Clonal propagation of primate offspring by embryo splitting |
| 07/19/2001 | WO2001005969A3 Electron transfer proteins |
| 07/19/2001 | WO2001005820A3 Method for down-regulating gdf-8 activity |
| 07/19/2001 | WO2001005791A3 NEW PROCESS FOR THE PREPARATION OF N-(1,1-DIMETHYLETHYL)-4-[[5'-ETHOXY-4-cis-[2-(4-MORFOLINO)ETHOXY]-2'-OXOSPIRO[CYCLOHEXAN-1,3'-[H]INDOL]-1'(2'H)-yl]-SULFONYL]-3-METHOXYBENZAMIDE AND ITS SALTS |
| 07/19/2001 | WO2001005392A3 Method for treating chronic pain using mek inhibitors |
| 07/19/2001 | WO2001004297A3 Human proteins having hydrophobic domains and dnas encoding these proteins |
| 07/19/2001 | WO2000073324A3 Modulation of gene expression in gastrointestinal inflammation |
| 07/19/2001 | WO2000064485A9 Specifically targeted catalytic antagonists and uses thereof |